Your browser doesn't support javascript.
Development and application of therapeutic antibodies against COVID-19.
Ning, Lin; Abagna, Hamza B; Jiang, Qianhu; Liu, Siqi; Huang, Jian.
  • Ning L; School of Healthcare Technology, Chengdu Neusoft University, Sichuan, China.
  • Abagna HB; School of Life Science and Technology, University of Electronic Science and Technology of China, Sichuan, China.
  • Jiang Q; Center for Informational Biology, University of Electronic Science and Technology of China, Sichuan, China.
  • Liu S; School of Life Science and Technology, University of Electronic Science and Technology of China, Sichuan, China.
  • Huang J; Center for Informational Biology, University of Electronic Science and Technology of China, Sichuan, China.
Int J Biol Sci ; 17(6): 1486-1496, 2021.
Article in English | MEDLINE | ID: covidwho-1206432
ABSTRACT
The pandemic of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) continues to be a global health crisis. Fundamental studies at genome, transcriptome, proteome, and interactome levels have revealed many viral and host targets for therapeutic interventions. Hundreds of antibodies for treating COVID-19 have been developed at preclinical and clinical stages in the format of polyclonal antibodies, monoclonal antibodies, and cocktail antibodies. Four products, i.e., convalescent plasma, bamlanivimab, REGN-Cov2, and the cocktail of bamlanivimab and etesevimab have been authorized by the U.S. Food and Drug Administration (FDA) for emergency use. Hundreds of relevant clinical trials are ongoing worldwide. Therapeutic antibody therapies have been a very active and crucial part of COVID-19 treatment. In this review, we focus on the progress of therapeutic COVID-19 antibody development and application, discuss corresponding problems and challenges, suggesting new strategies and solutions.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal Type of study: Prognostic study Limits: Humans Language: English Journal: Int J Biol Sci Journal subject: Biology Year: 2021 Document Type: Article Affiliation country: Ijbs.59149

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal Type of study: Prognostic study Limits: Humans Language: English Journal: Int J Biol Sci Journal subject: Biology Year: 2021 Document Type: Article Affiliation country: Ijbs.59149